Skip to the answer

IncobotulinumtoxinA Injection Uses, Dosage, Side Effects and Interactions

Brand name
Xeomin

Xeomin is a brand of incobotulinumtoxina injection that comes as an injection.

IncobotulinumtoxinA is a botulinum toxin injection that relaxes overactive muscles and reduces saliva-gland activity, used for chronic drooling, muscle stiffness and spasm conditions, and temporary improvement of upper facial lines.

Dr. Brian Staiger, PharmD, BCPS
Last reviewed Jul 10, 2026 Content updated Nov 7, 2026 Where our facts come from

Quick links

Ask Anything About IncobotulinumtoxinA InjectionType a question in your own words. Answered from its FDA label in seconds.

Every other section of this page is in the dots on the left edge of your screen: point at one to see where it goes.Every other section of this page is one tap away: use the arrow tab on the left edge of your screen.

IncobotulinumtoxinA Injection in Short

The Pharmacist’s Take

Dr. Brian Staiger, PharmD, BCPS
Clinical pharmacist Written

Xeomin (incobotulinumtoxinA) is a botulinum toxin, on the U.S. market since about 2010, that blocks the nerve signal acetylcholine so treated muscles relax and salivary glands quiet down; specialists use it for chronic drooling, arm stiffness (spasticity), cervical dystonia (neck spasms), blepharospasm (eyelid spasms) and temporary smoothing of upper facial lines. Most people tolerate it well, noticing injection site pain or bruising, dry mouth or headache, though neck and eyelid treatments can bring nearby weakness, swallowing trouble or a drooping lid. Its boxed warning is that the toxin can spread beyond the injection area, so get emergency care for trouble swallowing, speaking or breathing, even weeks later.

Key Takeaways From the HelloPharmacist Team

  • Expect a trained professional to inject it, with repeat sessions no sooner than every 12 weeks (every 16 weeks for drooling).
  • Results usually build over several days and fade over a few months as new nerve endings form, which is why treatment repeats.
  • Tell each prescriber you get Xeomin, since its units do not convert to other botulinum toxins and another within months can overweaken muscles.
  • Before each session, mention any swallowing or breathing trouble, a nerve or muscle condition, or an infection where the injection goes.

How we write and review this content: our editorial policy

FDA Boxed WarningThe FDA’s strongest safety alert. Read what it says about IncobotulinumtoxinA Injection.

The toxin’s effects can spread from the injection site to other parts of the body and cause serious, even life-threatening problems.

Symptoms can include general weakness, double or blurred vision, drooping eyelids, trouble swallowing or speaking, loss of bladder control and trouble breathing. They can start hours to weeks after injection, and deaths have been reported.

The risk is probably greatest in children treated for spasticity, but adults can be affected too, especially those with underlying conditions. Seek immediate medical care if you have swallowing, speech or breathing problems.

Read the full warning on DailyMed →

IncobotulinumtoxinA Injection by the Numbers

Strengths
3
in one form
Makers and packagers
2
Earliest FDA record
2010
Rank by Medicaid prescriptions
#989 of 1,682 drugs
More prescriptions than 41% of the 1,682 drugs we measure
8,147 prescriptions, Q1–Q4 2025

Patient Information Guide for IncobotulinumtoxinA Injection

What It’s Used For

Xeomin (incobotulinumtoxinA) is approved for these uses:

  • Chronic sialorrhea (long-term drooling) in people 2 years and older
  • Upper limb spasticity (arm muscle stiffness) in people 2 years and older
  • Cervical dystonia (neck muscle spasms) in adults
  • Blepharospasm (involuntary eyelid spasms) in adults
  • Temporary improvement of moderate to severe glabellar (frown) lines, horizontal forehead lines and lateral canthal lines (crow’s feet) in adults

How It Works

Xeomin enters the ends of nerves that control muscles and salivary glands. There it cuts a protein called SNAP25 that nerves need to release acetylcholine. Without that chemical signal, the muscle or gland quiets down.

The effect is not permanent. Over time, new nerve endings form and signaling returns.

Drug Class

Drug Class

  • Acetylcholine Release Inhibitor
  • Neuromuscular Blocker
Detailed classifications and sources

The FDA sorts a drug’s active ingredient by how it works, what it does in the body and its chemical structure, and gives it one main drug class.

Drug Class

Established Pharmacologic Class (EPC)
  • Acetylcholine Release Inhibitor
  • Neuromuscular Blocker

The main drug class the FDA gives it. It is the class named on the drug’s label.

How It Works

Mechanism of action (MoA)
  • Acetylcholine Release Inhibitors

What it does at the smallest level, such as a receptor or enzyme it blocks or switches on.

What It Does in the Body

Physiologic effect (PE)
  • Neuromuscular Blockade

A change it makes in how the body works.

Chemical Family

Chemical structure (CS)

None listed for IncobotulinumtoxinA Injection in the FDA’s index.

The chemical family it belongs to, by its structure.

The classes are the FDA’s own words, from its index of drug labels, published in the National Library of Medicine’s RxClass. Read the FDA’s definitions. Reference only, not medical advice.

Dosage

Xeomin is given by injection by a trained professional, into muscles or into salivary glands for drooling. It is not taken by mouth, so food does not apply.

  • Repeat treatments are spaced out, usually at least 12 to 16 weeks depending on the condition.
  • Facial lines should be retreated no more often than every three months.
  • Dose and injection sites are individualized to you.

If you miss a scheduled visit, ask your prescriber when to reschedule.

Typical Doses

Your prescriber chooses your dose, so take it exactly as prescribed.

Chronic drooling

Adults Usual dose 100 Units per treatment session
  • 100 Units per treatment session: 30 Units per parotid gland and 20 Units per submandibular gland (60 Units total parotid, 40 Units total submandibular), no sooner than every 16 weeks
Children 12 kg or more Usual dose 20 Units total per session

Step by step

  1. Parotid gland 6 Units each side (0.24 mL)
  2. Submandibular gland 4 Units each side (0.16 mL)
  3. Total 20 Units
Children 15 kg or more Usual dose 30 Units total per session

Step by step

  1. Parotid gland 9 Units each side (0.36 mL)
  2. Submandibular gland 6 Units each side (0.24 mL)
  3. Total 30 Units
Children 19 kg or more Usual dose 40 Units total per session

Step by step

  1. Parotid gland 12 Units each side (0.48 mL)
  2. Submandibular gland 8 Units each side (0.32 mL)
  3. Total 40 Units
Children 23 kg or more Usual dose 50 Units total per session

Step by step

  1. Parotid gland 15 Units each side (0.6 mL)
  2. Submandibular gland 10 Units each side (0.4 mL)
  3. Total 50 Units
Children 27 kg or more Usual dose 60 Units total per session

Step by step

  1. Parotid gland 18 Units each side (0.72 mL)
  2. Submandibular gland 12 Units each side (0.48 mL)
  3. Total 60 Units
Children 30 kg or more Usual dose 75 Units total per session

Step by step

  1. Parotid gland 22.5 Units each side (0.9 mL)
  2. Submandibular gland 15 Units each side (0.6 mL)
  3. Total 75 Units

Upper limb muscle stiffness (spasticity)

Adults Highest dose 400 Units total
  • Up to 400 Units total, divided among affected muscles
  • Repeat no sooner than every 12 weeks.
  • Per muscle: flexor digitorum superficialis 25 Units-100 Units (2 sites)
  • Flexor digitorum profundus 25 Units-100 Units (2 sites)
  • Flexor carpi radialis 25 Units-100 Units (1-2 sites)
  • Flexor carpi ulnaris 20 Units-100 Units (1-2 sites)
  • Brachioradialis 25 Units-100 Units (1-3 sites)
  • Biceps 50 Units-200 Units (1-4 sites)
  • Brachialis 25 Units-100 Units (1-2 sites)
  • Pronator quadratus 10 Units-50 Units (1 site)
  • Pronator teres 25 Units-75 Units (1-2 sites)
  • Flexor pollicis longus 10 Units-50 Units (1 site)
  • Adductor pollicis 5 Units-30 Units (1 site)
  • Flexor pollicis brevis/opponens pollicis 5 Units-30 Units (1 site)

Good to know

In patients not previously treated with a botulinum toxin, begin at the low end of the range

Children 2 years and older Highest dose 200 Units per single upper limb
  • Up to 8 Units/kg divided among affected muscles per single upper limb
  • 16 Units/kg if both upper limbs are treated
  • Repeat no sooner than every 12 weeks.
  • Per muscle (Units/kg, maximum Units, sites): brachioradialis 1-2, 50, 1-2
  • Biceps 2-3, 75, 1-3
  • Brachialis 1-2, 50, 1-2
  • Flexor carpi radialis 1, 25, 1
  • Flexor carpi ulnaris 1, 25, 1
  • Pronator quadratus 0.5, 12.5, 1
  • Pronator teres 1-2, 50, 1-2
  • Flexor digitorum superficialis 1, 25, 1
  • Flexor digitorum profundus 1, 25, 1
  • Flexor pollicis longus 1, 25, 1
  • Adductor pollicis 0.5, 12.5, 1
  • Flexor pollicis brevis/opponens pollicis 0.5, 12.5, 1

Neck muscle spasms (cervical dystonia)

For adults · Starting dose
Starting dose 120 Units per treatment session
  • Repeat generally no more often than every 12 weeks

Good to know

Previously treated patients: consider past dose, response, duration of effect and adverse events

Uncontrolled eyelid spasms (blepharospasm)

For adults · Starting dose
Starting dose 50 Units (25 Units per eye) Highest dose 100 Units per treatment session
  • Repeat no more often than every 12 weeks

Good to know

Previously treated with botulinum toxin A: consider past dose, response, duration of effect and adverse events

Upper facial lines

Adults Highest dose 64 Units
  • 64 Units: 20 Units for GL, 20 Units for HFL, 24 Units for LCL
  • Retreat no more frequently than every three months

GL stands for glabellar lines.

HFL stands for horizontal forehead lines.

LCL stands for lateral canthal lines.

Adults, frown lines between the eyebrows Usual dose 4 Units into each of 5 sites Highest dose 20 Units
  • 4 Units into each of 5 sites (2 in each corrugator muscle, 1 in the procerus muscle)
Adults, forehead lines treated with frown lines Highest dose 40 Units
  • 4 Units into each of 5 HFL sites (20 Units) and 4 Units into each of 5 GL sites (20 Units)

GL stands for glabellar lines.

HFL stands for horizontal forehead lines.

See the Full Dosing Instructions on DailyMed →

Side Effects

Side effects vary by what is being treated. Common ones include:

Common side effects

  • Dry mouth
  • Injection site pain or bruising
  • Neck pain and muscle weakness (cervical dystonia)
  • Trouble swallowing (cervical dystonia)
  • Drooping eyelid, dry eye or blurred vision (blepharospasm)
  • Cold-like symptoms such as nasopharyngitis, bronchitis or upper respiratory infection
  • Headache
  • Injection site pain, bruising or hematoma (blood collection under the skin)

When to get medical help

  • Get medical help right away for trouble swallowing, speaking or breathing, which can happen hours to weeks after injection.
  • Seek care for widespread muscle weakness, double or blurred vision, drooping eyelids or loss of bladder control.
  • Get emergency help for signs of a serious allergic reaction such as hives, swelling, wheezing or trouble breathing.
  • Tell your doctor about eye pain or irritation after eyelid treatment, as corneal damage can occur.
  • Seizures were reported in adults treated for upper limb spasticity.

Seek care right away for swallowing, speech or breathing trouble, widespread weakness, or signs of allergic reaction.

Warnings and Precautions

  • Spread of toxin effect: weakness, vision changes and swallowing or breathing problems can occur far from the injection site, hours to weeks later.
  • Swallowing and breathing: risk is higher with existing swallowing, breathing or neuromuscular conditions. Dysphagia can last months and sometimes require a feeding tube.
  • Allergic reactions: serious reactions including anaphylaxis have been reported.
  • Eyes: after eyelid treatment, reduced blinking can injure the cornea. Use caution with narrow-angle glaucoma risk.
  • Frown line treatment: eyelid drooping (ptosis) can occur, so doses and injection placement matter.
  • Units: Xeomin units cannot be converted to other botulinum toxins.
  • Human albumin: the product contains it, with an extremely remote risk of viral transmission.

Interactions

Some medicines can increase Xeomin’s muscle-weakening effect.

  • Aminoglycoside antibiotics and similar agents: can strengthen the toxin’s effect.
  • Muscle relaxants: may cause excessive weakness.
  • Anticholinergic drugs: may increase body-wide anticholinergic effects.
  • Other botulinum toxins: excessive weakness is possible if given close together.

Interactions Listed in the FDA-Approved Label

From the IncobotulinumtoxinA Injection prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.

  • Aminoglycosides and other agents interfering with neuromuscular transmission For example: tubocurarine-type muscle relaxants
    What happensThese agents may potentiate the effect of the toxin.
    What to doCo-administer only with caution and close observation.
  • Anticholinergic drugs
    What happensUse after administration of XEOMIN may potentiate systemic anticholinergic effects.
  • Other botulinum neurotoxin products
    What happensThe effect of giving different botulinum toxin products at the same time or within several months of each other is unknown; excessive neuromuscular weakness may be exacerbated.
  • Muscle relaxants
    What happensExcessive weakness may be exaggerated by a muscle relaxant given before or after XEOMIN.
Read the label’s full interactions text

7 DRUG INTERACTIONS Aminoglycosides or other agents that interfere with neuromuscular transmission may potentiate the effect of XEOMIN; co-administer only with caution and close observation 7.1 Aminoglycosides and Other Agents Interfering with Neuromuscular Transmission Co-administration of XEOMIN and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., tubocurarine-type muscle relaxants) should only be performed with caution as these agents may potentiate the effect of the toxin. 7.2 Anticholinergic Drugs Use of anticholinergic drugs after administration of XEOMIN may potentiate systemic anticholinergic effects. 7.3 Other Botulinum Neurotoxin Products The effect of administering different botulinum toxin products at the same time or within several months of each other is unknown. Excessive neuromuscular weakness may be exacerbated by administration of another botulinum toxin prior to the resolution of the effects of a previously administered botulinum toxin. 7.4 Muscle Relaxants Excessive weakness may also be exaggerated by administration of a muscle relaxant before or after administration of XEOMIN.

Read the full Drug Interactions section on DailyMed →

Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.

Before You Start

  • Do not use with a known allergy to botulinum toxins or the ingredients.
  • Do not use with infection at the injection site.
  • Tell your doctor about swallowing or breathing problems, ALS, myasthenia gravis or Lambert-Eaton syndrome.
  • Tell your doctor about eye surgery, narrow-angle glaucoma risk, facial asymmetry or eyelid drooping.
  • Pregnancy: use only if the benefit justifies the risk. Animal studies showed harm at high doses.
  • Breastfeeding: there are no data on milk or infant effects, so discuss it with your doctor.
  • Children: not established for several uses, and not for those under 2 years.
  • Older adults: no overall differences seen, though increased sensitivity cannot be ruled out.

Overdose

Too much Xeomin can cause widespread muscle weakness and, in severe cases, paralysis of breathing muscles that may need breathing support. Symptoms may not appear right away, so a person should be medically monitored for several weeks. Antitoxin exists but will not reverse effects already present.

How Your Body Processes It

At recommended doses, Xeomin cannot be detected in the blood after injection into muscle or salivary glands. That means its action stays mostly local to the injection area.

Storage

Store unopened vials of XEOMIN at or below 25°C (77°F). Refrigeration of unopened vials is not required. Stored in a refrigerator at 2°C to 8°C (36°F to 46°F) for up to 24 hours until time of use .

Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI

IncobotulinumtoxinA Injection: Pharmacist Answers to Common Questions

Quick, plain-English answers to the questions patients ask most about IncobotulinumtoxinA Injection — the kind of thing our pharmacy team would talk through with you at the counter.

What is Xeomin used for?

It treats chronic drooling, arm muscle stiffness (upper limb spasticity), neck spasms (cervical dystonia) and eyelid spasms (blepharospasm). It is also used in adults to temporarily smooth frown lines, forehead lines and crow’s feet. Which one applies depends on your own diagnosis.

How is Xeomin given and how often?

A trained professional injects it into the right muscles or salivary glands. Repeat treatments are spaced weeks to months apart, and your prescriber decides the timing. Facial line treatments should be no more often than every three months.

What side effects should I expect?

Common ones include injection site pain or bruising and dry mouth. Depending on the area treated, you might have neck pain, muscle weakness, a drooping eyelid, dry eye or cold-like symptoms.

When should I get medical help after an injection?

Get help right away if you have trouble swallowing, speaking or breathing, or notice widespread weakness, double vision or loss of bladder control. These can happen hours to weeks after the injection. Also seek emergency care for hives, swelling or wheezing.

Can I get Xeomin if I take other medicines?

Tell your prescriber about everything you take. Aminoglycoside antibiotics, muscle relaxants and anticholinergic drugs can increase Xeomin’s effects, and other botulinum toxins given close together can cause too much weakness.

Is Xeomin safe during pregnancy or breastfeeding?

There are not enough data in pregnant women, and animal studies showed harm at high doses, so it is used only if the benefit outweighs the risk. For breastfeeding, there are no data, so talk with your doctor about the balance.

Is IncobotulinumtoxinA injection available over the counter?

No. IncobotulinumtoxinA injection is a prescription medicine: every IncobotulinumtoxinA injection product listed with the FDA is prescription only, so it is not sold over the counter. Your prescriber decides whether it is appropriate for you, and your pharmacist dispenses it.

When was IncobotulinumtoxinA injection first available?

The earliest FDA record we hold for IncobotulinumtoxinA injection is from 2010: its first approval in Drugs@FDA or its earliest product listing in the NDC Directory, whichever is older. Many older medicines were in use before their first formal FDA approval, so this is the earliest date on record, not necessarily when IncobotulinumtoxinA injection was first used.

Who makes IncobotulinumtoxinA injection?

2 companies currently list IncobotulinumtoxinA injection products in the FDA's NDC Directory, including Merz Pharmaceuticals, LLC, Merz North America, Inc.. That count includes repackagers and distributors as well as manufacturers (companies that sell only the raw ingredient are not counted), so fewer companies actually make it; the label on your bottle names the one that supplied yours.

What is the brand name of IncobotulinumtoxinA injection?

IncobotulinumtoxinA injection is the generic name. Its brand name is Xeomin.

What is the generic name of Xeomin?

The generic name of Xeomin is IncobotulinumtoxinA injection. A generic name is the name of the active ingredient, the same whichever company makes the medicine; a brand name belongs to one company. Your prescription label may show either name.

What drug class is IncobotulinumtoxinA injection?

IncobotulinumtoxinA injection belongs to the drug class Acetylcholine Release Inhibitor and Neuromuscular Blocker, its established pharmacologic class on the FDA label.

What strengths does IncobotulinumtoxinA injection come in?

IncobotulinumtoxinA injection is listed in the FDA's National Drug Code Directory in these forms and strengths. Injection (into a muscle): 50 [USP'U], 100 [USP'U] and 200 [USP'U]. A listing does not mean every pharmacy stocks every strength.

Where can I read the IncobotulinumtoxinA injection prescribing information (package insert)?

The full FDA-approved prescribing information for IncobotulinumtoxinA injection, also called the package insert or drug label, is published on DailyMed, the National Library of Medicine's library of FDA labels. Each company's version has its own label; this page is built from Merz North America, Inc.'s, revised Jul 10, 2026, and links to it on DailyMed.

Is IncobotulinumtoxinA injection gluten free?

No IncobotulinumtoxinA injection label we read lists an ingredient made from wheat, barley or rye, the grains that carry gluten, and none names a starch, dextrin or maltodextrin without saying where it comes from. We read the FDA labels of 8 IncobotulinumtoxinA injection products from 2 companies. A label lists ingredients; it is not a gluten test, so we cannot promise that any product has no gluten. If you have celiac disease, ask the company for a written gluten statement. Our Inactive Ingredient Checker shows each company's IncobotulinumtoxinA injection by strength and NDC, and whether its label lists a gluten source, lactose, dyes or any other inactive ingredient. See IncobotulinumtoxinA injection inactive ingredients by company

Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI

Ask Anything About IncobotulinumtoxinA Injection

Skip the scrolling. Ask in your own words and get an answer from IncobotulinumtoxinA Injection’s FDA label and our pharmacists’ own work.

Try:

Name another drug or a supplement in your question and we check both.

AI answers from FDA labels and our own records, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist.How this works
  • Sources: IncobotulinumtoxinA Injection’s FDA label, including the clinical studies it reports, and the label of any drug you name; our pharmacists’ own work, such as our Do Not Crush list and our published answers to readers’ questions; our pharmacy prices and the Natural Medicines supplement database.
  • Written by AI: Answers are written by AI from those sources, and AI can make mistakes. Check what you read here with your doctor or pharmacist before you act on it.
  • Reviewed afterward: Our pharmacy team reviews every question and answer afterward to check it for accuracy, and when we find an error, we correct how the box answers. Read more in How we use AI.
  • Not medical advice. In an emergency, call 911, Poison Control at 1-800-222-1222, or 988.

More About IncobotulinumtoxinA Injection on HelloPharmacist

Still have a question? A licensed pharmacist answers for free, as soon as they can.
Detailed Data & References for IncobotulinumtoxinA Injection Forms and strengths, pricing, billing codes, manufacturers, safety reports and sourcing: the data behind the page. Most people can stop here. Each section below opens on a tap.

IncobotulinumtoxinA Injection Forms and Strengths (How It Comes)

IncobotulinumtoxinA Injection comes in 1 dose form, the injection. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.

Need a version that does not list lactose, a gluten source, a dye or gelatin? Inactive ingredients differ by manufacturer: see IncobotulinumtoxinA Injection inactive ingredients by manufacturer.

Injection

Into a muscle
Brands Xeomin
How this form is used
What it may be used for
  • Xeomin is used for chronic sialorrhea and upper limb spasticity in people 2 years and older.
  • Xeomin is used for cervical dystonia and blepharospasm in adults.
  • Xeomin is used for temporary improvement of upper facial lines in adults.
Important instructions
  • Xeomin is injected into muscles or, for drooling, into the parotid and submandibular salivary glands.
  • Xeomin is mixed (reconstituted) before use, for one patient and one session only.
  • Xeomin repeat treatments are spaced at least 12 to 16 weeks apart for most uses, and no more often than every three months for facial lines.
  • Xeomin units are not interchangeable with other botulinum toxin products.
Available strengths 3 strengths
8 FDA-listed product records ⓘ

IncobotulinumtoxinA Injection on the U.S. Market: Products, Makers and Brands

How IncobotulinumtoxinA Injection appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.

2 companies list 8 IncobotulinumtoxinA Injection product records with the FDA, mostly as injection; the earliest marketing or approval year on record is 2010. The one brand name in the directory today is Xeomin; the rest are generics.

1
Dose forms ⓘ
2
Labelers (makers, repackagers, distributors)
1
Brand names ⓘ
8
FDA-listed product records ⓘ
2010
Earliest FDA record ⓘ
Merz Pharmaceuticals, LLC63%
Merz North America, Inc.38%

Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.

How Widely IncobotulinumtoxinA Injection Is Used (Medicaid Data)

How many IncobotulinumtoxinA Injection prescriptions Medicaid paid for in Q1–Q4 2025, every brand, strength and form together. Medicaid is one program, so total U.S. use is higher.

8,147
Medicaid prescriptions filled (Q1–Q4 2025)
$7.6M paid by Medicaid, before rebates

How commonly is IncobotulinumtoxinA Injection prescribed? Of the 1,682 medications we measure, IncobotulinumtoxinA Injection ranks #989 by Medicaid prescriptions — more than 41% of them.

Where IncobotulinumtoxinA Injection ranks among the drugs we measure · Q1–Q4 2025 · neighbors ±5

Utilization by IncobotulinumtoxinA Injection product

Pick a strength and form to see its own numbers. Brand and generic versions are counted together.

Other IncobotulinumtoxinA Injection products: packs and listings not matched to one strength and form

8,147 Medicaid prescriptions (Q1–Q4 2025) 100% of IncobotulinumtoxinA Injection prescriptions shown $7.6M paid by Medicaid, before rebates ≈ $932 per prescription, before rebates

3 of 10 listed NDCs had Medicaid claims.

Dollars are what Medicaid paid before the rebates drug makers send back, so its real cost is lower.

Source: Medicaid State Drug Utilization Data (CMS), all states. 3 of the 10 listed IncobotulinumtoxinA Injection NDCs had Medicaid claims.

Compare IncobotulinumtoxinA Injection Products

A representative set of FDA-listed product records for IncobotulinumtoxinA Injection — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)

Strength Route Manufacturer / Labeler Category ⓘ Details
💊Injection
50 [USP'U] Intramuscular Merz North America, Inc. × 2 listings BLA View NDC →
100 [USP'U] Intramuscular Merz North America, Inc. BLA View NDC →
50 [USP'U] Intramuscular Merz Pharmaceuticals, LLC × 2 listings BLA View NDC →
100 [USP'U] Intramuscular Merz Pharmaceuticals, LLC × 2 listings BLA View NDC →
200 [USP'U] Intramuscular Merz Pharmaceuticals, LLC BLA View NDC →

Showing 8 of 8 products — FDA National Drug Code Directory. See every product, package size and price: browse all 8 IncobotulinumtoxinA Injection NDCs →

IncobotulinumtoxinA Injection Recall History

A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.

The FDA’s enforcement reports list no IncobotulinumtoxinA recalls since July 2021.

✅No IncobotulinumtoxinA recalls on record since July 2021

Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Nov 19, 2026.

IncobotulinumtoxinA Injection Brand Names

IncobotulinumtoxinA Injection has one brand name on record: Xeomin. A brand name is one company's name for the medicine; a generic has the same active ingredient under its generic name.

Xeomin

Who Makes IncobotulinumtoxinA Injection: Manufacturers and Labelers

2 companies list IncobotulinumtoxinA Injection products with the FDA. By number of product records, the largest are Merz Pharmaceuticals, LLC, Merz North America, Inc.. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.

Merz Pharmaceuticals, LLC 5 Merz North America, Inc. 3

Sources for This IncobotulinumtoxinA Injection Page

Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.

📄
FDA-filed drug labels (SPL) Uses, dosing, warnings & side effects from SPL records retrieved through openFDA; the linked representative set can be verified on DailyMed. Prescribing information dated Jul 10, 2026, the label version this page reads. A label changes when the FDA approves new uses, doses or warnings, so this is not the day the page itself last changed. Read the full label on DailyMed
🏭
Forms, brands & labelersAggregated from ingredient-matched FDA National Drug Code Directory product records for IncobotulinumtoxinA Injection.
📈
Real-world reportsThe FDA Adverse Event Reporting System (FAERS), served through openFDA.
🚨
Recalls & shortagesopenFDA drug-enforcement reports and the FDA drug-shortage database.

Where this information comes from

The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 2 clinical label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source.

Clinical labels in scope
2
Finished products in the current FDA directory
8
Companies listing them (makers, repackagers, distributors)
2
FDA labeler codes behind them ⓘ
2
Linked representative label ⓘ
Merz North America, Inc.
Linked label effective
Jul 10, 2026
Composite sections available
23
Linked SPL Set ID
3f35d6e0-3450-4abc-a0da-cc7b277e7c6e
Linked SPL Document ID
8b2d961a-6bb4-4bef-ac07-7dcc2bbfacc7
Open the linked representative label on DailyMed ↗

How this page is built

HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. Merz North America, Inc. is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →